An Exploratory Study of Single-Dose and Multiple-Doses IBI3042 in Healthy, Overweight, or Obese Participants

The goal of this study is to learn about the safety and tolerability of IBI3042, aninvestigational oral drug that activates the glucagon‐like peptide‐1 (GLP‐1) receptor.The study will also assess how IBI3042 moves through the body and explore its effects onbody weight and related measures. Researchers will evaluate whether single and multipleoral doses of IBI3042 can be administered with acceptable safety and tolerability.The study has two parts. In Part A, healthy or overweight participants will receive asingle oral dose of IBI3042 or placebo. In Part B, overweight or obese participants willreceive multiple oral doses of IBI3042 or placebo over 29 days. Participants will beassigned to different dose groups, and dose escalation will be guided by safety,tolerability, and available drug concentration data from earlier groups.Participants will undergo safety assessments and blood sampling during the study. Theseassessments will include medical examinations, vital signs, laboratory tests, andelectrocardiograms. In Part B, researchers will also assess changes in body weight, bodymass index, waist circumference, and other metabolic measures.